An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Progressive Supranuclear Palsy (PSP)

In brief

The purpose of this study was to assess the long-term safety and efficacy of ABBV-8E12 (tilavonemab) in participants with progressive supranuclear palsy (PSP).

Key facts

Study ID

NCT03391765

Run by

AbbVie

People needed

142

Starts

2018-01-24

Expected to finish

2019-12-13

Last updated by the study team

2021-02-03

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant completed the 52-week treatment period in Study M15-562 (NCT02985879)
• In the opinion of the investigator, the participant was compliant during participation in Study M15-562 (NCT02985879)
• Participant has an identified, reliable, study partner (e.g., caregiver, family member, social worker, or friend)

You may not qualify if…

• Participants who weigh less than 44 kg (97 lbs) at the time of study entry
• Any contraindication or inability to tolerate brain magnetic resonance imaging (MRI)
• Participant has any significant change in his/her medical condition that could interfere with the subject's participation in the study, could place the subject at increased risk, or could confound interpretation of study results
• More than 8 weeks have elapsed since the participant received his/her last dose of study drug in Study M15-562 (NCT02985879)
• Participant is considered by the investigator, for any reason, to be an unsuitable candidate to receive ABBV-8E12 or the participant is considered by the investigator to be unable or unlikely to comply with the dosing schedule or study evaluations

Where it is running

• Univ Alabama-Birmingham /ID# 165522 — Birmingham, Alabama, United States
• Mayo Clinic Arizona /ID# 165521 — Phoenix, Arizona, United States
• Cedars-Sinai Medical Center /ID# 165567 — Beverly Hills, California, United States
• Usc /Id# 165529 — Los Angeles, California, United States
• University of California, Los Angeles /ID# 165669 — Los Angeles, California, United States
• University of California, San /ID# 165560 — San Diego, California, United States
• Univ California, San Francisco /ID# 165553 — San Francisco, California, United States
• Rocky Mountain Movement Disorders Center /ID# 165559 — Englewood, Colorado, United States
• UF Center for Movement Disorde /ID# 165561 — Gainesville, Florida, United States
• Mayo Clinic /ID# 165554 — Jacksonville, Florida, United States
• University of South Florida /ID# 165556 — Tampa, Florida, United States
• Augusta University Medical Center /ID# 165562 — Augusta, Georgia, United States
• Rush University Medical Center /ID# 165527 — Chicago, Illinois, United States
• University of Chicago Medical /ID# 165555 — Chicago, Illinois, United States
• Indiana University /ID# 165519 — Indianapolis, Indiana, United States
• University of Kentucky Chandler Medical Center /ID# 165566 — Lexington, Kentucky, United States
• Mayo Clinic - Rochester /ID# 165518 — Rochester, Minnesota, United States
• Cleveland Clinic Lou Ruvo Cent /ID# 165538 — Las Vegas, Nevada, United States
• Rutgers Robert Wood Johnson /ID# 165526 — New Brunswick, New Jersey, United States
• Columbia Univ Medical Center /ID# 165528 — New York, New York, United States
• Cleveland Clinic Main Campus /ID# 165537 — Cleveland, Ohio, United States
• Vanderbilt Univ Med Ctr /ID# 165520 — Nashville, Tennessee, United States
• Kerwin Research Center /ID# 206872 — Dallas, Texas, United States
• McGovern Medical School /ID# 165565 — Houston, Texas, United States
• Q-Pharm Pty Limited /ID# 165452 — Herston, Queensland, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.